ADC Therapeutics Reduces Workforce by 17% to Prioritize Key Drug

ADC Therapeutics is implementing a reorganization plan, which includes a 17% reduction in its global workforce. This strategic move aims to redirect resources towards its Zynlonta franchise, anticipating annual savings of approximately $10 million. The decision follows recent safety concerns related to a trial for one of its cancer medications.